Johnson & Johnson (JNJ.US) released its 3Q24 results today. The company's sales in MedTech segment turned out to be lower than market forecasts, however, on the profitability level J&J positively surprised the market. The company's stock price is approaching the upper limits of the broad downtrend the company has been in since the beginning of this year.
Source: xStation
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appThe company reported sales of $22.47 billion, a slight improvement over the previous year (+5.5% y/y). The strongest sales growth was recorded by the Darzalex product, whose revenues increased by 21% y/y. In the MedTech segment, the company reported PLN 7.89 billion, which was weaker than market expectations.
Adj. EPS fared better, coming in at $2.42, beating expectations of $2.19/share. The adjustment included about $3 billion in one-time event costs related to legal and acquisition costs.
Johnson & Johnson lowered its profitability projections for the full year 2024, mainly due to the V-Wave acquisition. The company's new projections call for adjusted earnings per share in the range of: $9.88-$9.98 (vs. previous projections of $9.97-$10.07).
3Q24 RESULTS:
- Sales $22.47 billion, estimates $22.16 billion
- MedTech revenues $7.89 billion, +5.8% y/y, estimates $8.03 billion
- Imbruvica revenues $753 million, -6.8% y/y, estimates $746.2 million
- Darzalex revenues $3.02 billion, +21% y/y, $2.94 billion estimate
- Erleada revenues $790 million, estimate $766.4 million
- Tremfya revenues $1.01 billion, +13% y/y, $1.06 billion estimate
- Remicade revenues $419 million, -9.1% y/y, $324.7 million estimate
- Stelar revenues $2.68 billion, -6.6% y/y, $2.61 billion estimate
- Zytiga revenues $150 million, -30% y/y, $144.2 million estimate
- Xarelto revenues $592 million, -5.3% y/y, $563.5 million estimate
- Simponi revenues $516 million, -18% y/y, $476.9 million estimate
- Adjusted EPS $2.42, estimate $2.19
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
